Comparative Pharmacology
Head-to-head clinical analysis: ROPIVACAINE HYDROCHLORIDE versus XYLOCAINE 5 W GLUCOSE 7 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROPIVACAINE HYDROCHLORIDE versus XYLOCAINE 5 W GLUCOSE 7 5.
ROPIVACAINE HYDROCHLORIDE vs XYLOCAINE 5% W/ GLUCOSE 7.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ropivacaine is an amide-type local anesthetic that reversibly blocks nerve impulse propagation by inhibiting sodium ion influx via voltage-gated sodium channels in neuronal cell membranes.
Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses.
0.2% to 0.5% solution; epidural: 15-30 mg bolus, then 6-14 mg/hour infusion; peripheral nerve block: 0.5% solution, 20-30 mL; local infiltration: 0.2% solution, up to 200 mg total.
Adult: 5-25 mL (250-1250 mg lidocaine) of 5% lidocaine with glucose 7.5% solution, administered by caudal or lumbar epidural injection, single dose. Max total dose: 1250 mg.
None Documented
None Documented
Terminal elimination half-life: 1.8–2.7 hours (mean 2.0 h) in adults. In neonates, prolonged to 3–6 hours due to immature hepatic clearance.
1.5-2 hours (terminal); prolonged in heart failure, hepatic disease, or elderly; neonates 3-6 hours due to immature hepatic function.
Renal: 86% as metabolites and unchanged drug (primarily 3-hydroxy-ropivacaine and 4-hydroxy-ropivacaine glucuronides). Fecal: <1%. Biliary: minor.
Hepatic metabolism (90% N-dealkylation by CYP1A2/CYP3A4 to monoethylglycinexylidide and glycinexylidide); renal excretion of metabolites and parent drug (<10% unchanged); <1% biliary/fecal.
Category A/B
Category C
Local Anesthetic
Local Anesthetic